BioCentury
ARTICLE | Targets & Mechanisms

Switching targets to avoid resistance to CAR Ts

Overcoming resistance to traditional CAR Ts with CARs against an alternative B cell target

September 25, 2019 10:26 PM UTC

City of Hope researchers have engineered CAR T cells directed against a new B cell target that could overcome resistance to or replace canonical CAR Ts.

The novel CAR T therapy against TNFRSF13c, which was showcased in a Science Translational Medicine paper published Wednesday, has been licensed to PeproMene Bio Inc. The Irvine, Calif.-based company will fund a Phase I trial in acute lymphoblastic leukemia (ALL) patients who have relapsed following anti-CD19 therapy. ...

BCIQ Company Profiles

City of Hope